Concepedia

Mark L. Hartman

ML

72

Publications

9K

Citations

47

H-Index

1984

Active since

Affiliations

University of Virginia(Current)

Eli Lilly (United States)

University of Virginia Health System

Stanford University

Indiana University – Purdue University Indianapolis

Mark L. Hartman is an author at University of Virginia specializing in medicine, endocrinology, and physiology.

ORCID

Top concepts

Publications per year

1984–2025

72

Publications

72

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 830 citations

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Rohit Loomba, Mark L. Hartman, Eric Lawitz et al. · New England Journal of Medicine · 2024 · 611 citations

Sensitivity and Specificity of Six Tests for the Diagnosis of Adult GH Deficiency

Beverly M. K. Biller, Mary H. Samuels, Anthony J. Zagar et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 404 citations · Full text

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 327 citations

, , +6

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman, Arun J. Sanyal, Rohit Loomba et al. · Diabetes Care · 2020 · 321 citations · Full text

Rows per page

1–5 of 72